1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
The Oncology Institute, Inc.

The Oncology Institute, Inc.

TOIIW
The Oncology Institute, Inc.US flagNASDAQ Capital Market
0.06
USD
- -
- -
5.42MMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
113
155
188
203
252
324
393
503
546
Operating Margin (%)
4.23
-1.7
-4.37
-22.59
-28.52
-18.55
-15.28
-7.18
-5.99
Depreciation Expense
1
3
3
3
4
6
6
7
7
Net Income, GAAP
4
-4
-14
-11
- -
-83
-65
-61
-44
Effective Tax Rate (%)
18.78
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
3.49
-2.59
-7.64
-5.38
0.06
-25.62
-16.44
-12.06
-7.97
Working Capital
- -
8
1
124
101
109
60
42
38
LT Debt
- -
- -
7
- -
103
113
116
97
97
Total Equity
- -
42
28
104
123
57
4
-16
-16
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
7
7
7
LT Borrowings
76
77
79
LT Finance Leases
20
19
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
98
99
100
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
110
113
117
Cash, Cash Equivalents & STI
28
34
30
Accounts Receivable, Net
60
59
58
Inventories
19
17
24
Total Current Liabilities
66
71
79
Payables & Accruals
38
48
57
ST Debt
7
7
7
Deferred Revenue
5
2
2

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-79.3%
-538.01%
Free Cash Flow
- -
1,024.58%
-8.38%
Net Income, GAAP
- -
-10,980.7%
-6.27%
Sales/Revenue/Turnover
- -
22.03%
27.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
95
99
100
100
393
2025
104
120
137
142
503
2026
147
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Daniel Virnich
Full Time Employees
825
Sector
Healthcare
Industry
Medical - Care Facilities
Address
18000 Studebaker Road Cerritos CA United States of America 90703
IPO Date
Nov 12, 2021
CIK
0001799191
Website
theoncologyinstitute.com
Similar Companies
Greenbrook TMS Inc. (GTMS.TO)
New York Health Care, Inc. (BBAL)
PharmaCom BioVet, Inc. (PHMB)
Dr. Sulaiman Al Habib Medical Services Group Company (4013.SR)
Jinxin Fertility Group Limited (1951.HK)
Skylight Health Group Inc. (SLHGP)
Business
The Oncology Institute, Inc. (NASDAQ: TOI) operates as a leading value-based community oncology provider, delivering specialized cancer care services across the United States through its three core segments of Dispensary, Patient Services, and Clinical Trials & Other; it offers physician services, in-house infusion and dispensary operations, radiation therapy, clinical trials management, outpatient blood product transfusions, stem cell transplants, palliative care programs, hematology treatments, surgical oncology, high-precision radiation, chemotherapy, immunotherapy, targeted therapies, hormonal therapies, financial counseling, educational seminars, support groups, counseling services, and 24/7 patient assistance. The company serves adult and senior cancer patients at over 100 clinics and affiliate locations in five states, focusing on personalized, evidence-based treatments that prioritize long-term health outcomes and quality of life in community settings. Founded in 2007 and headquartered in Cerritos, California, The Oncology Institute employs over 120 clinicians and 700 teammates, targeting a patient population exceeding 1.8 million while partnering with pharmaceutical and medical device companies for innovative trial access. In March 2025, it completed a $16.5 million private placement with accredited investors including management and board members, plus a $4.1 million debt exchange with Deerfield Management, to fund organic growth and working capital; it also enhanced its research collaboration with Helios Clinical Research for expanded clinical trials, launched six new contracts adding over 250,000 lives in late 2024, secured improved drug supplier discounts, and announced a September 2025 partnership with Protocol Behavioral Health for integrated mental health support in cancer care.